Kazutaka Hosoya

Kyoto, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

Correction: Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells.

Correction: Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells.

Journal: Cancer research
Published: June 26, 2026

Anti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8+ T cell responses and promoting tertiary lymphoid structure formation.

Anti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8+ T cell responses and promoting tertiary lymphoid structure formation.

Journal: Nature communications
Published: September 17, 2025

Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells.

Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells.

Journal: Cancer research
Published: August 04, 2025

Durvalumab consolidation after chemoradiotherapy for locoregional recurrent non-small cell lung cancer.

Durvalumab consolidation after chemoradiotherapy for locoregional recurrent non-small cell lung cancer.

Journal: Molecular and clinical oncology
Published: November 20, 2024

Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAF V600E Mutated Lung Adenocarcinoma via Survivin Downregulation.

Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAF V600E Mutated Lung Adenocarcinoma via Survivin Downregulation.

Journal: Cancer science
Published: November 14, 2024

Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study.

Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study.

Journal: BMC cancer
Published: July 05, 2024

Performance status improvement and advances in systemic treatment after brain metastases resection: a retrospective single-center cohort study of non-small cell lung cancer patients.

Performance status improvement and advances in systemic treatment after brain metastases resection: a retrospective single-center cohort study of non-small cell lung cancer patients.

Journal: BMC cancer
Published: November 25, 2023

Aurora kinase B inhibition in small-cell lung cancer: BCL-2 as a potential therapeutic biomarker and combination target.

Aurora kinase B inhibition in small-cell lung cancer: BCL-2 as a potential therapeutic biomarker and combination target.

Journal: Translational lung cancer research
Published: November 20, 2023

Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation-positive Lung Cancer.

Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation-positive Lung Cancer.

Journal: Molecular cancer therapeutics
Published: June 14, 2023

CD47 polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancer.

CD47 polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancer.

Journal: Oncology letters
Published: April 11, 2023

Author Correction: Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer.

Author Correction: Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer.

Journal: Scientific reports
Published: February 07, 2023

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer.

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer.

Journal: NPJ precision oncology
Published: September 21, 2022
Showing 1-12 of 29

Last Updated: 09/26/2026